FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors
Medical Disclaimer: The information provided in this article is for educational and informational purposes only. It is not intended to
Topic
Understanding Cancer
31 articles on Understanding Cancer, written for patients and carers arranging specialty treatment.
-
-
Prostate Cancer Screening: When Should Men Get Tested?
Prostate cancer is one of the most common cancers affecting men worldwide. Fortunately, when caught early, it is also one
-
Bone Marrow Transplant: A Complete Guide for Patients
The realization that you or someone close to you needs a bone marrow transplant can be extremely daunting. It may
-
Radiation Therapy Side Effects: A Complete Guide for Patients
Being under cancer treatment may be an intimidating experience, particularly considering the possibility of radiation therapy. Even though radiation therapy
-
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
-
What are the 4 stages of lung cancer?
Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 7, 2026. n Lung cancer staging is a
-
First-Line Palbociclib Combination Boosts PFS in HR+/HER2+ mBC – PATINA Findings
Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 1, 2026. n Metastatic breast cancer (mBC) remains
-
Sunvozertinib vs Chemo: A PFS Breakthrough in EGFR+ NSCLC
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 25, 2026. n The treatment landscape for EGFR-mutated
-
Healing After Radiation: Is a Nipple-Sparing Mastectomy Possible?
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 20, 2026. n For many years, patients who
-
ESGO 2026 Insights: The Future of Ovarian Cancer Care
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 14, 2026. n The 27th European Congress on
Still have a question?
We reply to every enquiry within one working day.